Societal CDMO, Inc.

Equities

SCTL

US75629F1093

Pharmaceuticals

Market Closed - Nyse 04:00:00 2024-04-05 pm EDT 5-day change 1st Jan Change
1.1 USD +0.92% Intraday chart for Societal CDMO, Inc. 0.00% +213.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Societal CDMO, Inc. Announces Board and Committee Resignations CI
Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index CI
CoreRx, Inc. completed the acquisition of Societal CDMO, Inc. from First Light Asset Management, LLC and Others. CI
Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from S&P TMI Index CI
North American Morning Briefing : Stocks Edge -2- DJ
Societal CDMO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Markets on Hold -2- DJ
Stephens Downgrades Societal CDMO to Equalweight From Overweight, Raises Price Target to $1.10 From $1 MT
William Blair Downgrades Societal CDMO to Market Perform From Outperform MT
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts MT
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session MT
RBC Downgrades Societal CDMO to Sector Perform From Outperform, Trims Price Target to $1.10 From $1.25 Amid CoreRx Deal MT
CoreRx, Inc. entered into a definitive agreement to acquire Societal CDMO, Inc.. CI
Societal CDMO Signs Co-Marketing Deal With Benuvia Operations MT
Societal CDMO, Inc and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers CI
Certain Warrants of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023. CI
Certain Restricted Stock Units of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023. CI
Certain Stock Options of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023. CI
Certain Common Stock of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023. CI
RBC Cuts Price Target on Societal CDMO to $1.25 From $2, Keeps Outperform Rating MT
Transcript : Societal CDMO, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Earnings Flash (SCTL) SOCIETAL CDMO Posts Q3 Revenue $23.6M, vs. Street Est of $24.3M MT
Societal CDMO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Societal CDMO, Inc. Resets Earnings Guidance for the Year 2023 CI
Societal CDMO, Inc. Reduces its Workforce by 26 Positions Across All Aspects of the Business CI
Chart Societal CDMO, Inc.
More charts
Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus in the area of small molecules. It is a CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company's key products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR and Donnatal liquids and tablets. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms, with specialization in modified release technologies and facilities to handle potent compounds and controlled substances.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock Market
  2. Equities
  3. SCTL Stock
  4. News Societal CDMO, Inc.
  5. Societal CDMO Receives Non-Compliance Notice From Nasdaq